New Risk • May 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Announcement • Mar 31
China Reform Health Management and Services Group Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026 China Reform Health Management and Services Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Breakeven Date Change • Mar 31
Forecast to breakeven in 2026 The analyst covering China Reform Health Management and Services Group expects the company to break even for the first time. New forecast suggests the company will make a profit of CN¥8.22m in 2026. Average annual earnings growth of 125% is required to achieve expected profit on schedule. Announcement • Dec 31
China Reform Health Management and Services Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026 China Reform Health Management and Services Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026 Board Change • Nov 08
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Dongxing Wang was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 30
Third quarter 2025 earnings released: CN¥0.04 loss per share (vs CN¥0.043 profit in 3Q 2024) Third quarter 2025 results: CN¥0.04 loss per share (down from CN¥0.043 profit in 3Q 2024). Revenue: CN¥74.9m (up 19% from 3Q 2024). Net loss: CN¥39.3m (down 194% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Sep 30
China Reform Health Management and Services Group Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 China Reform Health Management and Services Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Announcement • Jul 02
China Reform Health Management and Services Group Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025 China Reform Health Management and Services Group Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 Announcement • Jun 05
China Reform Health Management and Services Group Co., Ltd., Annual General Meeting, Jun 26, 2025 China Reform Health Management and Services Group Co., Ltd., Annual General Meeting, Jun 26, 2025, at 15:00 China Standard Time. Location: Building 2 and Building 3, Yard No. 22, Shatan Backstreet, Dongcheng District, Beijing China New Risk • May 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Announcement • May 08
China Reform Health Management and Services Group Co., Ltd. Announces Executive Changes China Reform Health Management and Services Group Co., Ltd. held its 1st Extraordinary General Meeting of 2025 on May 6, 2025, during which the following proposals were approved: Election of non-independent directors: Wang Dongxing and Song Min. Election of independent directors: Sun Na. Announcement • Mar 31
China Reform Health Management and Services Group Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025 China Reform Health Management and Services Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 New Risk • Jan 12
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Announcement • Dec 31
China Reform Health Management and Services Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025 China Reform Health Management and Services Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025 Reported Earnings • Oct 26
Third quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.027 loss in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.043 (up from CN¥0.027 loss in 3Q 2023). Revenue: CN¥62.8m (up 3.3% from 3Q 2023). Net income: CN¥42.0m (up CN¥65.6m from 3Q 2023). Profit margin: 67% (up from net loss in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
China Reform Health Management and Services Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024 China Reform Health Management and Services Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Reported Earnings • Aug 29
Second quarter 2024 earnings released: CN¥0.033 loss per share (vs CN¥0.045 loss in 2Q 2023) Second quarter 2024 results: CN¥0.033 loss per share (improved from CN¥0.045 loss in 2Q 2023). Revenue: CN¥89.5m (up 102% from 2Q 2023). Net loss: CN¥32.6m (loss narrowed 21% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. New Risk • Jul 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (8.6% increase in shares outstanding). Announcement • Jul 20
Hainan Xinghui Investment Co., Ltd. agreed to acquire 18.96% stake in Hainan Haihong Chemical Fiber Industry Co., Ltd. from China Reform Health Management and Services Group Co., Ltd. (SZSE:000503) for approximately CNY 110 million. Hainan Xinghui Investment Co., Ltd. agreed to acquire 18.96% stake in Hainan Haihong Chemical Fiber Industry Co., Ltd. from China Reform Health Management and Services Group Co., Ltd. (SZSE:000503) for approximately CNY 110 million on September 27, 2023. The deal has been approved by the board of China Reform Health Management and Services Group and on October 16, 2023 shareholders of China Reform Health Management also approved the deal. Announcement • Jun 29
China Reform Health Management and Services Group Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024 China Reform Health Management and Services Group Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Announcement • Jun 08
China Reform Health Management and Services Group Co., Ltd., Annual General Meeting, Jun 26, 2024 China Reform Health Management and Services Group Co., Ltd., Annual General Meeting, Jun 26, 2024, at 15:00 China Standard Time. Location: Jia No. 18, Hexi Lane, Xiba, Chaoyang District, Beijing China Reported Earnings • Apr 27
First quarter 2024 earnings released: CN¥0.041 loss per share (vs CN¥0.048 loss in 1Q 2023) First quarter 2024 results: CN¥0.041 loss per share (improved from CN¥0.048 loss in 1Q 2023). Revenue: CN¥47.9m (down 14% from 1Q 2023). Net loss: CN¥40.4m (loss narrowed 7.9% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Mar 30
China Reform Health Management and Services Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 China Reform Health Management and Services Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Announcement • Dec 30
China Reform Health Management and Services Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024 China Reform Health Management and Services Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024 New Risk • Dec 13
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Shareholders have been diluted in the past year (8.6% increase in shares outstanding). New Risk • Nov 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 29
Third quarter 2023 earnings released: CN¥0.027 loss per share (vs CN¥0.049 loss in 3Q 2022) Third quarter 2023 results: CN¥0.027 loss per share (improved from CN¥0.049 loss in 3Q 2022). Revenue: CN¥60.8m (up 17% from 3Q 2022). Net loss: CN¥23.6m (loss narrowed 47% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Sep 30
China Reform Health Management and Services Group Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023 China Reform Health Management and Services Group Co., Ltd. announced that they will report Q3, 2023 results at 3:00 PM, China Standard Time on Oct 28, 2023 Reported Earnings • Aug 25
Second quarter 2023 earnings released: CN¥0.045 loss per share (vs CN¥0.025 loss in 2Q 2022) Second quarter 2023 results: CN¥0.045 loss per share (further deteriorated from CN¥0.025 loss in 2Q 2022). Revenue: CN¥44.4m (flat on 2Q 2022). Net loss: CN¥41.1m (loss widened 82% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 5% per year. Announcement • Jun 02
China Reform Health Management and Services Group Co., Ltd., Annual General Meeting, Jun 28, 2023 China Reform Health Management and Services Group Co., Ltd., Annual General Meeting, Jun 28, 2023, at 15:00 China Standard Time. Agenda: To consider the 2022 annual report and its summary; to consider the 2022 work report of the board of directors; to consider the 2022 work report of the supervisory committee; to consider the 2022 annual accounts; to consider the 2022 profit distribution plan; to approve the Repurchase and cancellation of some restricted stocks under the 1st phase restricted stock incentive plan; to approve the 2022 remuneration for directors and senior management; to approve the 2022 remuneration for supervisors; to approve the Appointment of 2023 audit firm and determination of its audit fees; to approve the Amendments to the Company's articles of association; to approve the Amendments to the Company's rules of procedure governing the board meetings; to consider the Amendments to the Company's rules of procedure governing shareholders' general meetings; and to consider other matters if any. Reported Earnings • Apr 28
First quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.054 loss in 1Q 2022) First quarter 2023 results: CN¥0.048 loss per share (improved from CN¥0.054 loss in 1Q 2022). Revenue: CN¥55.8m (up 47% from 1Q 2022). Net loss: CN¥43.9m (loss narrowed 11% from 1Q 2022). Revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Board Change • Dec 21
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Non-Independent Director Tao Chen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Dianzhong Yang was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 28
Third quarter 2022 earnings released: CN¥0.049 loss per share (vs CN¥0.035 loss in 3Q 2021) Third quarter 2022 results: CN¥0.049 loss per share (further deteriorated from CN¥0.035 loss in 3Q 2021). Revenue: CN¥52.1m (up 6.1% from 3Q 2021). Net loss: CN¥44.6m (loss widened 40% from 3Q 2021). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 11
Second quarter 2022 earnings released: CN¥0.025 loss per share (vs CN¥0.044 loss in 2Q 2021) Second quarter 2022 results: CN¥0.025 loss per share (up from CN¥0.044 loss in 2Q 2021). Revenue: CN¥44.5m (up 76% from 2Q 2021). Net loss: CN¥22.5m (loss narrowed 43% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Announcement • May 07
China Reform Health Management and Services Group Co., Ltd., Annual General Meeting, Jun 21, 2022 China Reform Health Management and Services Group Co., Ltd., Annual General Meeting, Jun 21, 2022, at 15:00 China Standard Time. Agenda: To consider 2021 annual report and its summary; to consider 2021 work report of the board of directors; to consider 2021 work report of the supervisory committee; to consider 2021 annual accounts; to consider 2021 profit distribution plan; to consider 2022 reappointment of audit firm and determination of the audit fees; to consider 2021 remuneration for directors, supervisors and senior management; and to consider Amendments to the Company's articles of association. Reported Earnings • May 02
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: CN¥0.054 loss per share (up from CN¥0.063 loss in 1Q 2021). Revenue: CN¥38.0m (up 38% from 1Q 2021). Net loss: CN¥49.4m (loss narrowed 12% from 1Q 2021). Revenue missed analyst estimates by 80%. Earnings per share (EPS) were also behind analyst expectations. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Board Change • Apr 27
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Non-Independent Director Dianzhong Yang was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 14
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: CN¥0.20 loss per share (up from CN¥0.27 loss in FY 2020). Revenue: CN¥252.5m (up 22% from FY 2020). Net loss: CN¥175.8m (loss narrowed 28% from FY 2020). Revenue missed analyst estimates by 80%. Earnings per share (EPS) were also behind analyst expectations. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Announcement • Mar 31
China Reform Health Management and Services Group Co., Ltd. Announces Executive Changes China Reform Health Management and Services Group Co., Ltd. approved Election of non-independent directors: 1.1. Yang Dianzhong; 1.2. Li Yonghua; 1.3. Jiang Kaihong; 1.4. Chen Tao; 1.5. Liu Yingjie and 1.6. Sun Dicao also Election of independent directors: 2.1. Wang Xiuli; 2.2. Bai Yan and 2.3. Sun Jie. Reported Earnings • Oct 31
Third quarter 2021 earnings released: CN¥0.035 loss per share (vs CN¥0.047 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CN¥49.2m (up 70% from 3Q 2020). Net loss: CN¥31.8m (loss narrowed 25% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 29
Second quarter 2021 earnings released: CN¥0.044 loss per share (vs CN¥0.054 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CN¥25.2m (up 11% from 2Q 2020). Net loss: CN¥39.3m (loss narrowed 19% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 25
First quarter 2021 earnings released: CN¥0.063 loss per share (vs CN¥0.079 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CN¥27.4m (up 60% from 1Q 2020). Net loss: CN¥56.3m (loss narrowed 21% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Jan 29
New 90-day low: CN¥7.11 The company is down 31% from its price of CN¥10.26 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 11% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥7.70 The company is down 34% from its price of CN¥11.58 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 12% over the same period. Is New 90 Day High Low • Dec 15
New 90-day low: CN¥9.82 The company is down 15% from its price of CN¥11.59 on 16 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 12% over the same period. Is New 90 Day High Low • Oct 15
New 90-day low: CN¥10.82 The company is down 12% from its price of CN¥12.34 on 17 July 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 17% over the same period. Is New 90 Day High Low • Sep 26
New 90-day low: CN¥10.87 The company is down 5.0% from its price of CN¥11.41 on 24 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 11% over the same period. Announcement • Aug 11
China Reform Health Management and Services Group Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020 China Reform Health Management and Services Group Co., Ltd. announced that they will report first half, 2020 results on Aug 28, 2020 
